Business
Renalytix Convenes Panel at VA Healthcare Summit
Renalytix Convenes Panel at VA Healthcare Summit.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8663R\n Renalytix PLC\n 10 November 2021\n \n \n \n \n \n \n \n Renalytix plc\n \n \n (\"Renalytix\" or the \"Company\")\n \n \n \n \n \n Renalytix Convenes Expert Panel at VA Healthcare Summit \n \n \n \n \n \n Leading clinicians discuss enabling long-term kidney health in Veterans with type 2 diabetes and early-stage chronic kidney disease\n \n \n \n \n \n \n NEW YORK and SALT LAKE CITY, November 10, 2021 - \n \n In recognition of National Diabetes Month and concurrent with the launch of KidneyIntelX in the Veterans Health Administration health system, \n \n Renalytix\n \n (NASDAQ: RNLX) (LSE: RENX) \n convened a multidisciplinary panel to discuss advances in kidney health through early-stage prognosis and intervention of chronic kidney disease (CKD) in patients with type 2 diabetes. Clinical experts shared patient case studies drawing from their experience adding KidneyIntelX into clinical care. The KidneyIntelX enabled care pathway being implemented in the Mount Sinai Health System is a model that can be used in implementing the new Veterans Health Administration CKD Directive and joint VA and Department of Defense guideline, driving care earlier to prevent progression and kidney failure. The panel event took place at The Institute for Defense and Government Advancement (IDGA) VA Healthcare Summit on Wednesday, October 27, 2021. \n \n \n \n \n \n The panel, \"Breakthrough Diagnostic Approach for Type 2 Diabetes and Early-Stage Chronic Kidney Disease (CKD): Today's Precise Answer, Tomorrow's Kidney Health,\"\n included renowned thought leaders who highlighted the importance of early detection and intervention to promote long-term kidney health and improve clinical outcomes in their type 2 diabetes patients. \n \n \n \n \n \n Commenting on the Summit discussion, panelists said: \n \n \n \n \n \n \n Michael J. Donovan, PhD, MD, Chief Medical Officer at Renalytix: \n \n \n \"This roundtable discussion provided a unique opportunity for clinical experts to highlight the impact of KidneyIntelX risk assessment on patient-specific management decisions. Their remarks highlighted how KidneyIntelX testing can help address the challenges they face when relying on current clinical tools. The panel also reviewed the practice-changing evidence from recent th...